See how Chugai compares to other companies
Domestic Sales of Prescribed Drugs (Reimbursement Price Basis)
Chugai was ranked 3rd in Japan to surpass ¥500 billion in domestic sales of prescribed drugs on reimbursement price basis (-2.4% year on year) for four consecutive years due to the sales expansion of its own products, and strong market penetration of new products in-licensed from Roche. (January-December, 2024)
- The strategic alliance with Roche has enabled Chugai to in-license Roche’s groundbreaking products and efficiently develop and launch them in Japan, which has built a stable revenue base for Chugai.
- As for Chugai originated products, Actemra®, Alecensa®, Hemlibra®, and Enspryng® have been growing steadily. In addition, PiaSky®, which was launched in May 2024, is steadily penetrating the market. As for in-licensed Roche products, favorable sales of new products, such as Phesgo® and Vabysmo® is also the main drivers of revenue growth. However, sales decreased YoY due to the supply of Ronapreve to the government, which was recognized in the previous fiscal year.
Ratio of Operating Expenses to Revenues
Chugai has consistently maintained a low ratio of operating expenses to revenues compared with its industry peers in Japan.
- In anticipation of a rise in the ratio of cost of sales to sales due to the increase in products in-licensed from Roche, thorough cost-cutting measures have been implemented. The ratio of operating expenses to revenues reaches to a level comparable with the world’s leading pharmaceutical companies aside from peers in Japan.
- As a general principle, we strive to keep the rate of increase in operating expenses within the rate of revenue growth.
Ratio of Operating Profit to Revenues
Chugai’s ratio of operating profit to revenues has risen due to the growth of Chugai originated products in both Japan and overseas.
- While we market in-licensed Roche products in Japan, we also out-license our originated products to Roche, which have a lower cost of sales to sales ratio.
- The ratio of operating profit to revenue significantly improved to 46.3%, due to decreased cost of sales and increased income related to Hemlibra and one-time income.
